Expression of c-kit and p53 in Non-small Cell Lung Cancers.
- Author:
Jinyoung YOO
1
;
Chi Hong KIM
;
So Hyang SONG
;
Byoung Yong SHIM
;
Youn Ju JEONG
;
Meyung Im AHN
;
Sung Whan KIM
;
Deog Gon CHO
;
Min Seop JO
;
Kyu Do CHO
;
Hong Joo CHO
;
Hoon Kyo KIM
Author Information
1. Department of Pathology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Immunohistochemistry;
c-kit;
p53;
Vascular endothelial growth factor;
cd34
- MeSH:
Adenocarcinoma;
Antibodies;
Carcinoma;
Carcinoma, Non-Small-Cell Lung;
Carcinoma, Squamous Cell;
Humans;
Immunohistochemistry;
Lung Neoplasms*;
Lung*;
Proto-Oncogene Proteins c-kit;
Small Cell Lung Carcinoma;
Vascular Endothelial Growth Factor A
- From:Cancer Research and Treatment
2004;36(3):167-172
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Increasing experimental evidence indicates that abnormal expression of c-kit may be implicated in the pathogenesis of a variety of solid tumors. It has been reported that over 70% of small cell lung cancer (SCLC) contain the c-kit receptor. In the present study, a c-kit analysis has been extended to non-small cell lung cancer (NSCLC). The expressions of p53, vascular endothelial growth factor (VEGF) and cd34, in addition to c-kit, were evaluated to investigate the correlations between these proteins and to determine their potential relationships with the clinicopathological data. MATERIALS AND METHODS: Paraffin-embedded tumor sections, obtained from 147 patients with NSCLC, were immunohistochemically investigated using anti-c-kit, anti- p53, anti-VEGF and anti-cd34 antibodies. RESULTS: c-kit was expressed in 40 (27%) of the tumors examined: 27% of the adenocarcinomas, 27% of the squamous cell carcinomas and 29% of the undifferentiated carcinomas. p53 and VEG F immunoreactivities were present in 107 (73%) and 110 (75%) carcinomas, respectively. Anti-cd34 was negative in all samples. No associations were established among these proteins. The c-kit, however, showed a strong correlation with the T factor: T1 (n=11), 0%; T2 (n=49), 16% and T3 (n=87), 37% (p=.006). CONCLUSION: It is suggested that in NSCLC c-kit is expressed relatively frequently and may become a therapeutic target for the patients with inoperable or recurrent c-kit positive tumors. The alterations in p53 probably constitute an early event, whereas the activated c-kit may contribute to tumor progression.
